SCIENTIFIC AWARD ASTRAZENECA FOUNDATION 2024

New advances in diagnosis/treatment of monogenic rare diseases

REGULATIONS

Art. 1. On the initiative of AstraZeneca Foundation, the Research Foundation Flanders (FWO) and Fonds de la Recherche Scientifique-FNRS (F.R.S.-FNRS) will grant in 2024 the Scientific Award AstraZeneca Foundation in new advances in diagnosis/treatment of monogenic rare diseases, which amounts to 25.000 EURO. Half of this amount will be attributed to the laureate for personal use, the other half of the amount will be paid to the host lab of the laureate to further research in the domain of new advances in diagnosis/treatment of monogenic rare diseases.

Art. 2. The Scientific Award AstraZeneca Foundation – New advances in diagnosis/treatment of monogenic rare diseases 2024 rewards innovative scientific research leading to new advances in diagnosis/treatment of monogenic rare diseases. It intends to reward an established investigator on the basis of his/her previous work, with a perspective of future development in the same field.

Art. 3. The applicant should be active in the above mentioned field of research, with both ongoing work related to the focus of the prize and future prospects. The research outline should specify the past and ongoing work of the applicant in the field of research (description of four (4) pages at most), followed by one (1) page in which the candidate elaborates on his/her further plans to continue the research, detailing e.g. the future prospects of the obtained achievements and the results which clinical or experimental study might generate in the following three years.

Art. 4. The award will be granted on the basis of the recommendations of a jury of experts, appointed jointly by FWO and F.R.S.-FNRS according to the applicable rules of FWO and F.R.S.-FNRS. If no suitable candidate can be identified, the award will not be granted. In this case, the AstraZeneca Foundation will, in close consultation with both FWO and F.R.S.-FNRS, attribute the complete amount of the award to a scientific goal within the core business of FWO and F.R.S.-FNRS.

Art. 5. The Award cannot be divided amongst several researchers.

..
Art. 6. The award can only be given to an **individual scientist from postdoctoral level onwards who is affiliated to a Belgian university or university hospital at the deadline of the call**. Prior to the submission deadline, the applicant must have held a research position in Belgium for at least five years (in a consecutive or cumulated period). **The applicant must have obtained the first PhD degree maximum 15 years before the date of the submission deadline** (possibly extended in case of eligible career breaks). For each continuous period of 365 days between the date of the PhD degree and the application, maximum one extension of one year of the abovementioned seniority limit may be granted, if during this period continuous periods of at least 3 months, regardless of the number, have occurred because of maternity leave, full-time parental leave, full-time sickness leave or military service/compulsory civilian service in the country of which they are citizen.

Art. 7. Personnel of the AstraZeneca Foundation or affiliated to the AstraZeneca Foundation are not eligible for the Award.

Art. 8. Applicants **may not have received an Award for the work submitted** with the same amount (or higher) in the last 3 years (at the deadline of the call).

Art. 9. Applicants for the **Scientific Award AstraZeneca Foundation – New advances in diagnosis/treatment of monogenic rare diseases 2024** cannot apply for any other Award granted by the AstraZeneca Foundation in the same year.

Art. 10. Applications have to be submitted electronically using the appropriate form at the latest on **10 June 2024 by midnight CEST**. The form is available on the website **www.frs-fnrs.be** and has to be sent by e-mail to **prix@frs-fnrs.be**. The form has to be completed in English.

Art. 11. Any problems or disputes arising from the eligibility of submitted applications or from granting the Award will be settled by the F.R.S.-FNRS and the FWO, whose decision in these respects will be final.

Art. 12. The scientific outline, presentations and evaluation reports generated in the framework of this Scientific Award will be treated confidentially.

April 2024.